A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Identifieur interne : 000076 ( PubMed/Corpus ); précédent : 000075; suivant : 000077A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Auteurs : Mariana Baz ; Myeisha Paskel ; Yumiko Matsuoka ; James R. Zengel ; Xing Cheng ; John J. Treanor ; Hong Jin ; Kanta SubbaraoSource :
- Journal of virology [ 1098-5514 ] ; 2015.
English descriptors
- KwdEn :
- Adolescent, Aged, Aged, 80 and over, Animals, Antibodies, Viral (blood), Dogs, Female, Ferrets, Humans, Influenza A Virus, H3N2 Subtype (immunology), Influenza A Virus, H3N8 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza Vaccines (isolation & purification), Male, Mice, Inbred BALB C, Middle Aged, Orthomyxoviridae Infections (prevention & control), Recombination, Genetic, Reverse Genetics, Vaccination (methods), Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Influenza Vaccines.
- immunology : Influenza A Virus, H3N2 Subtype, Influenza A Virus, H3N8 Subtype, Influenza Vaccines.
- chemical , isolation & purification : Influenza Vaccines.
- methods : Vaccination.
- prevention & control : Orthomyxoviridae Infections.
- Adolescent, Aged, Aged, 80 and over, Animals, Dogs, Female, Ferrets, Humans, Male, Mice, Inbred BALB C, Middle Aged, Recombination, Genetic, Reverse Genetics, Young Adult.
Abstract
H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.
DOI: 10.1128/JVI.00280-15
PubMed: 25903333
Links to Exploration step
pubmed:25903333Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.</title><author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zengel, James R" sort="Zengel, James R" uniqKey="Zengel J" first="James R" last="Zengel">James R. Zengel</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name><affiliation><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25903333</idno><idno type="pmid">25903333</idno><idno type="doi">10.1128/JVI.00280-15</idno><idno type="wicri:Area/PubMed/Corpus">000076</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000076</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.</title><author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zengel, James R" sort="Zengel, James R" uniqKey="Zengel J" first="James R" last="Zengel">James R. Zengel</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name><affiliation><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><affiliation><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Dogs</term><term>Female</term><term>Ferrets</term><term>Humans</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza A Virus, H3N8 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (genetics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (isolation & purification)</term><term>Male</term><term>Mice, Inbred BALB C</term><term>Middle Aged</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Recombination, Genetic</term><term>Reverse Genetics</term><term>Vaccination (methods)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A Virus, H3N8 Subtype</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Dogs</term><term>Female</term><term>Ferrets</term><term>Humans</term><term>Male</term><term>Mice, Inbred BALB C</term><term>Middle Aged</term><term>Recombination, Genetic</term><term>Reverse Genetics</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25903333</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>13</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.</ArticleTitle><Pagination><MedlinePgn>6907-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00280-15</ELocationID><Abstract><AbstractText Label="UNLABELLED">H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Although natural infection of humans with an avian H3N8 influenza virus has not yet been reported, this influenza virus subtype has already crossed the species barrier and productively infected mammals. Pandemic preparedness is an important public health priority. Therefore, we generated a live attenuated avian H3N8 vaccine candidate and demonstrated that a single dose of the vaccine was highly immunogenic and protected mice and ferrets against homologous and heterologous H3N8 avian viruses.</AbstractText><CopyrightInformation>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baz</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paskel</LastName><ForeName>Myeisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zengel</LastName><ForeName>James R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treanor</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053123" MajorTopicYN="N">Influenza A Virus, H3N8 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059386" MajorTopicYN="N">Reverse Genetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25903333</ArticleId><ArticleId IdType="pii">JVI.00280-15</ArticleId><ArticleId IdType="doi">10.1128/JVI.00280-15</ArticleId><ArticleId IdType="pmc">PMC4468475</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2003 May 16;21(17-18):1974-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12706686</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jan 8;25(4):612-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17005299</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2009;154(5):887-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19396578</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation><ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S82-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15577936</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):66-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Mar 1;199(5):711-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19210163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 2;375(9708):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20018365</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1995 Jul;172(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7797897</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Aug 15;208(4):594-602</Citation><ArticleIdList><ArticleId IdType="pubmed">23656978</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2014 Apr;22(4):183-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24582528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Apr 12;29(17):3144-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21377509</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 2010 Aug 26;144(3-4):455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20153940</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Jun;87(12):6901-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23576512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Oct;81(19):10558-66</Citation><ArticleIdList><ArticleId IdType="pubmed">17634234</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1986 Jan;23(1):66-72</Citation><ArticleIdList><ArticleId IdType="pubmed">3700610</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Jun 22;336(6088):1534-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22723413</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Aug 6;27(36):4953-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19540952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Nov;84(22):11950-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20810733</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):453-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19444146</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014;5:4791</Citation><ArticleIdList><ArticleId IdType="pubmed">25183346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Vet Med Assoc. 1963 Sep 15;143:587-90</Citation><ArticleIdList><ArticleId IdType="pubmed">14077956</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Nov 28;32(50):6798-804</Citation><ArticleIdList><ArticleId IdType="pubmed">25446831</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 21;310(5747):482-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16186182</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012;3(4):e00166-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22851656</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3872457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2814-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15709000</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Mar;88(5):2867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24371061</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2013 Jun;20(6):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23576673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2014 Jun 15;209(12):1860-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24604819</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10801978</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Aug;86(16):8625-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22674976</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Feb;89(3):1652-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25410860</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1998 Jan 1;160(1):322-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9551987</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2014;385:359-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24990620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2008 Oct;118(10):3273-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18802488</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Virol. 2014 May 1;9(5):513-524</Citation><ArticleIdList><ArticleId IdType="pubmed">25214882</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Jun 21;486(7403):420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22722205</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jan;83(1):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18945773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 8;27(28):3744-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19464558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1984 Jul;20(1):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">6205018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000076 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000076 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25903333
|texte= A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25903333" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |